Search

everythinglearnresearchcommunity

for

Search:↓

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

The user is considering adding RU58841 to liquid minoxidil without propylene glycol (PG) due to an allergy and is asking if this combination is effective and if PG is necessary. They have been using finasteride and minoxidil foam, plan to use RU58841 with liquid minoxidil in the evening, and continue finasteride.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

Topical androgen receptor antagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.

The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Users inquire about experiences with Pyrilutamide Kx group buys.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

The user mixed RU58841 with Minoxidil for hair loss treatment and experienced reduced hair fall and thicker hair but stopped due to chest pain and muscle twitching. They plan to use a new routine without RU58841 or Finasteride due to side effects, including various topical treatments and peptides.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.

Gugo Vine Bark shampoo is discussed as a potential hair loss treatment, but opinions vary on its effectiveness. Some suggest using proven treatments like finasteride, minoxidil, or ketoconazole instead.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

The conversation discusses the use of pyrrolidinyl diaminopyrmidine oxide (triaminodil) compared to minoxidil for hair loss treatment. The user is considering switching from 5% minoxidil to a product containing 5% triaminodil.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.

Hair transplants, oral finasteride, oral minoxidil, and dutasteride mesotherapy are highly effective for treating AGA hair loss. This combination can maintain and improve hair for most people, except those with very aggressive AGA.

Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.

A user discusses a topical prescription for hair regrowth containing Minoxidil, Finasteride, and Latanoprost, noting Latanoprost's side effect of promoting eyelash and eyebrow growth. Others share experiences and information about Latanoprost, highlighting its origins as a glaucoma drug and potential side effects.